I-GONAD

A robust method for in situ germline genome engineering using CRISPR nucleases

Masato Ohtsuka, Masahiro Sato, Hiromi Miura, Shuji Takabayashi, Makoto Matsuyama, Takayuki Koyano, Naomi Arifin, Shingo Nakamura, Kenta Wada, Channabasavaiah B Gurumurthy

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We present a robust method called improved-Genome editing via Oviductal Nucleic Acids Delivery (i-GONAD) that delivers CRISPR ribonucleoproteins to E0.7 embryos via in situ electroporation. The method generates mouse models containing single-base changes, kilobase-sized deletions, and knock-ins. The efficiency of i-GONAD is comparable to that of traditional microinjection methods, which rely on ex vivo handling of zygotes and require recipient animals for embryo transfer. In contrast, i-GONAD avoids these technically difficult steps, and it can be performed at any laboratory with simple equipment and technical expertise. Further, i-GONAD-treated females retain reproductive function, suggesting future use of the method for germline gene therapy.

Original languageEnglish (US)
Article number25
JournalGenome biology
Volume19
Issue number1
DOIs
StatePublished - Feb 26 2018

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
nucleases
nucleic acid
Nucleic Acids
nucleic acids
germ cells
engineering
genome
Genome
embryo
Professional Competence
ribonucleoproteins
Ribonucleoproteins
Electroporation
electroporation
gene therapy
Zygote
Embryo Transfer
Microinjections
zygote

Keywords

  • CRISPR
  • Easi-CRISPR
  • GONAD
  • In vivo electroporation
  • Knock-in
  • Long ssDNA
  • Transgenic mouse

ASJC Scopus subject areas

  • Ecology, Evolution, Behavior and Systematics
  • Genetics
  • Cell Biology

Cite this

I-GONAD : A robust method for in situ germline genome engineering using CRISPR nucleases. / Ohtsuka, Masato; Sato, Masahiro; Miura, Hiromi; Takabayashi, Shuji; Matsuyama, Makoto; Koyano, Takayuki; Arifin, Naomi; Nakamura, Shingo; Wada, Kenta; Gurumurthy, Channabasavaiah B.

In: Genome biology, Vol. 19, No. 1, 25, 26.02.2018.

Research output: Contribution to journalArticle

Ohtsuka, M, Sato, M, Miura, H, Takabayashi, S, Matsuyama, M, Koyano, T, Arifin, N, Nakamura, S, Wada, K & Gurumurthy, CB 2018, 'I-GONAD: A robust method for in situ germline genome engineering using CRISPR nucleases', Genome biology, vol. 19, no. 1, 25. https://doi.org/10.1186/s13059-018-1400-x
Ohtsuka M, Sato M, Miura H, Takabayashi S, Matsuyama M, Koyano T et al. I-GONAD: A robust method for in situ germline genome engineering using CRISPR nucleases. Genome biology. 2018 Feb 26;19(1). 25. https://doi.org/10.1186/s13059-018-1400-x
Ohtsuka, Masato ; Sato, Masahiro ; Miura, Hiromi ; Takabayashi, Shuji ; Matsuyama, Makoto ; Koyano, Takayuki ; Arifin, Naomi ; Nakamura, Shingo ; Wada, Kenta ; Gurumurthy, Channabasavaiah B. / I-GONAD : A robust method for in situ germline genome engineering using CRISPR nucleases. In: Genome biology. 2018 ; Vol. 19, No. 1.
@article{d269e280d81b4dc4bb0ea2080006cf91,
title = "I-GONAD: A robust method for in situ germline genome engineering using CRISPR nucleases",
abstract = "We present a robust method called improved-Genome editing via Oviductal Nucleic Acids Delivery (i-GONAD) that delivers CRISPR ribonucleoproteins to E0.7 embryos via in situ electroporation. The method generates mouse models containing single-base changes, kilobase-sized deletions, and knock-ins. The efficiency of i-GONAD is comparable to that of traditional microinjection methods, which rely on ex vivo handling of zygotes and require recipient animals for embryo transfer. In contrast, i-GONAD avoids these technically difficult steps, and it can be performed at any laboratory with simple equipment and technical expertise. Further, i-GONAD-treated females retain reproductive function, suggesting future use of the method for germline gene therapy.",
keywords = "CRISPR, Easi-CRISPR, GONAD, In vivo electroporation, Knock-in, Long ssDNA, Transgenic mouse",
author = "Masato Ohtsuka and Masahiro Sato and Hiromi Miura and Shuji Takabayashi and Makoto Matsuyama and Takayuki Koyano and Naomi Arifin and Shingo Nakamura and Kenta Wada and Gurumurthy, {Channabasavaiah B}",
year = "2018",
month = "2",
day = "26",
doi = "10.1186/s13059-018-1400-x",
language = "English (US)",
volume = "19",
journal = "Genome Biology",
issn = "1465-6906",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - I-GONAD

T2 - A robust method for in situ germline genome engineering using CRISPR nucleases

AU - Ohtsuka, Masato

AU - Sato, Masahiro

AU - Miura, Hiromi

AU - Takabayashi, Shuji

AU - Matsuyama, Makoto

AU - Koyano, Takayuki

AU - Arifin, Naomi

AU - Nakamura, Shingo

AU - Wada, Kenta

AU - Gurumurthy, Channabasavaiah B

PY - 2018/2/26

Y1 - 2018/2/26

N2 - We present a robust method called improved-Genome editing via Oviductal Nucleic Acids Delivery (i-GONAD) that delivers CRISPR ribonucleoproteins to E0.7 embryos via in situ electroporation. The method generates mouse models containing single-base changes, kilobase-sized deletions, and knock-ins. The efficiency of i-GONAD is comparable to that of traditional microinjection methods, which rely on ex vivo handling of zygotes and require recipient animals for embryo transfer. In contrast, i-GONAD avoids these technically difficult steps, and it can be performed at any laboratory with simple equipment and technical expertise. Further, i-GONAD-treated females retain reproductive function, suggesting future use of the method for germline gene therapy.

AB - We present a robust method called improved-Genome editing via Oviductal Nucleic Acids Delivery (i-GONAD) that delivers CRISPR ribonucleoproteins to E0.7 embryos via in situ electroporation. The method generates mouse models containing single-base changes, kilobase-sized deletions, and knock-ins. The efficiency of i-GONAD is comparable to that of traditional microinjection methods, which rely on ex vivo handling of zygotes and require recipient animals for embryo transfer. In contrast, i-GONAD avoids these technically difficult steps, and it can be performed at any laboratory with simple equipment and technical expertise. Further, i-GONAD-treated females retain reproductive function, suggesting future use of the method for germline gene therapy.

KW - CRISPR

KW - Easi-CRISPR

KW - GONAD

KW - In vivo electroporation

KW - Knock-in

KW - Long ssDNA

KW - Transgenic mouse

UR - http://www.scopus.com/inward/record.url?scp=85042549128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042549128&partnerID=8YFLogxK

U2 - 10.1186/s13059-018-1400-x

DO - 10.1186/s13059-018-1400-x

M3 - Article

VL - 19

JO - Genome Biology

JF - Genome Biology

SN - 1465-6906

IS - 1

M1 - 25

ER -